Skip to main content

Molecular Design and Synthesis Center

Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties

AUTHORS

Rai G , Urban DJ , Mott BT , Hu X , Yang SM , Benavides GA , Johnson MS , Squadrito GL , Brimacombe KR , Lee TD , Cheff DM , Zhu H , Henderson MJ , Pohida K , Sulikowski GA , Dranow DM , Kabir M , Shah P , Padilha E , Tao D , Fang Y , Christov PP , Kim K , Jana S , Muttil P , Anderson T , Kunda NK , Hathaway HJ , Kusewitt DF , Oshima N , Cherukuri M , Davies DR , Norenberg JP , Sklar LA , Moore WJ , Dang CV , Stott GM , Neckers L , Flint AJ , Darley-Usmar VM , Simeonov A , Waterson AG , Jadhav A , Hall MD , Maloney DJ , . Journal of medicinal chemistry. 2020 9 27; 63(19). 10984-11011

ABSTRACT

Lactate dehydrogenase (LDH) catalyzes the conversion of pyruvate to lactate, with concomitant oxidation of reduced nicotinamide adenine dinucleotide as the final step in the glycolytic pathway. Glycolysis plays an important role in the metabolic plasticity of cancer cells and has long been recognized as a potential therapeutic target. Thus, potent, selective inhibitors of LDH represent an attractive therapeutic approach. However, to date, pharmacological agents have failed to achieve significant target engagement , possibly because the protein is present in cells at very high concentrations. We report herein a lead optimization campaign focused on a pyrazole-based series of compounds, using structure-based design concepts, coupled with optimization of cellular potency, drug-target residence times, and PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition . The lead compounds, named () and (), possess desirable attributes for further studying the effect of LDH inhibition.

Tags: